Collplant biotechnologies reports first quarter 2021 financial results with record revenues of $14.5 million

Rehovot, israel, may 27, 2021 /prnewswire/ -- collplant (nasdaq: clgn), a regenerative and aesthetic medicine company, today announced financial results for the first quarter ended march 31, 2021 and provided an update on the company's business developments. collplant reported revenues of $14.5 million for the first quarter of 2021, a 2,281% increase from the $609,000 recorded in the first quarter of 2020 resulting primarily from the $14 million upfront payment received from allergan aesthetics, an abbvie company, in connection with the development agreement entered into in february 2021.
CLGN Ratings Summary
CLGN Quant Ranking